Coumarin-based Scaffolds as Multitarget Modulators of Chronic Inflammation: Insights into Inflammatory Signaling...

A wide range of chronic illnesses, including metabolic, autoimmune, neurodegenerative, and malignant conditions, are caused by the dysregulation of inflammation, a complex, multi-scale biological defense mechanism. Despite their clinical efficacy, current pharmacotherapies such as NSAIDs, corticosteroids, and biologics are constrained by side effects, insufficient resolution of inflammatory cascades, and poor long-term appropriateness. Interest in natural-product scaffolds with multi-target anti-inflammatory potential has increased due to these therapeutic gaps. Among these, 7-hydroxycoumarin (umbelliferone) has become a leading molecule due to its broad pharmacological spectrum, favorable safety profile, and ability to simultaneously target multiple pathogenic nodes. This review assesses how 7-hydroxycoumarin and its structural derivatives act at these biochemical and molecular intersections and offers an integrated and thorough analysis of inflammation pathways, including COX/LOX-derived eicosanoid biosynthesis, cytokine and chemokine signaling, oxidative and nitrosative stress, ECM degradation, and receptor-mediated immunomodulation. According to preclinical research, 7-hydroxycoumarin inhibits COX-2, iNOS, and MAPK/NF-κB signaling; modulates SOD/CAT/GSH to restore redox homeostasis; reduces cytokine overproduction; and protects tissues in models of oxidative stress, hepatic injury, ulcerative colitis, and inflammation associated with cancer. Its potency, stability, and pharmacokinetics have been improved by advances in synthetic approaches, hybrid design, metal-complex formation, and nanotechnology-based delivery. 7-hydroxycoumarin is positioned as a flexible, multi-target, next-generation scaffold for antiinflammatory drug development, with promising translational relevance for chronic inflammatory illnesses, according to the combined biochemical, pharmacological, and in-silico data.